JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Kura Oncology (NASDAQ:KURA) and maintained a price target of $32.

June 18, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Kura Oncology and maintained a price target of $32, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and a maintained price target of $32 by JMP Securities suggests strong confidence in Kura Oncology's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100